Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | M6PR | P20645 | 2/20 | 0.44 |
| ▸ | MGAM | O43451 | 4/20 | 0.40 |
| ▸ | SI | P14410 | 4/20 | 0.40 |
| ▸ | G6PD | P11413 | 2/20 | 0.38 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.38 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | SYNJ2 | O15056 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1004728 | 1.00 | M6PR (0.44) | M6PRMGAMSIG6PDFUCA1 | |
| SCHEMBL10268031 | 1.00 | M6PR (0.44) | M6PRMGAMSIG6PDFUCA1 | |
| SCHEMBL9611968 | 1.00 | M6PR (0.44) | M6PRMGAMSIG6PDFUCA1 | |
| SCHEMBL13510798 | 1.00 | M6PR (0.44) | M6PRMGAMSIG6PDFUCA1 | |
| SCHEMBL2502348 | 1.00 | M6PR (0.44) | M6PRMGAMSIG6PDFUCA1 | |
| SCHEMBL24605082 | 1.00 | M6PR (0.44) | M6PRMGAMSIG6PDFUCA1 | |
| SCHEMBL2743468 | 1.00 | M6PR (0.44) | M6PRMGAMSIG6PDFUCA1 | |
| SCHEMBL16726423 | 1.00 | M6PR (0.44) | M6PRMGAMSIG6PDFUCA1 | |
| SCHEMBL12588436 | 1.00 | M6PR (0.44) | M6PRMGAMSIG6PDFUCA1 | |
| SCHEMBL1919200 | 1.00 | M6PR (0.44) | M6PRMGAMSIG6PDFUCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607083-B1 | RAPID DETECTION OF E. COLI IN A THIN FILM CULTURE DEVICE | 3M INNOVATIVE PROPERTIES CO (US) | 2021-11-10 | — | — | EP | claimed |
| EP-1649043-B1 | METHOD FOR THE DETECTION OF COLIFORMS AND IN PARTICULAR ESCHERICHIA COLI | ISRIM S CONS A R L (IT) | 2010-12-15 | — | — | EP | claimed |
| EP-0983375-B1 | METHODS AND DEVICES FOR DETECTING BACTERIOPHAGE | MINNESOTA MINING & MFG (US) | 2005-01-12 | — | — | EP | claimed |
| EP-0791070-B1 | ENZYMATIC METHOD FOR DETECTING COLIFORM BACTERIA OR E. COLI | STUDIE EN SAMENWERKINGVERBAND (BE) | 2000-12-27 | — | — | EP | claimed |
| US-11771688-B2 | Pyridine derivatives substituted by heterocyclic ring and amino group | AMPLYX PHARMACEUTICALS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20160257709-A1 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | SUTRO BIOPHARMA, INC. | 2016-09-08 | — | — | US | disclosed |
| US-20070042030-A1 | Preparation for the application of agents in mini-droplets | IDEA AG (DE) | 2007-02-22 | — | — | US | disclosed |
| EP-0475160-B2 | Preparation for drug application in minute droplet form | IDEA AG (DE) | 2004-07-14 | — | — | EP | disclosed |
| US-6165500-A | Preparation for the application of agents in mini-droplets | IDEA AG (DE) | 2000-12-26 | — | — | US | disclosed |
| EP-0475160-B1 | Preparation for drug application in minute droplet form | IDEA AG (DE) | 1996-02-14 | — | — | EP | disclosed |
| EP-0475160-A1 | Preparation for drug application in minute droplet form | Cevc, Gregor, Prof. Dr. (DE) | 1992-03-18 | — | — | EP | disclosed |
| WO-1992003122-A1 | PREPARATION FOR APPLICATION OF ACTIVE SUBSTANCES IN THE FORM OF MINIMUM-SIZED DROPLETS | CEVC GREGOR (DE) | 1992-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160257709-A1 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | CYP17A1, HSD17B7, SHBG | M6PR 4726/4885MGAM 3917/4885SI 535/4885 |
| US-11771688-B2 | Pyridine derivatives substituted by heterocyclic ring and amino group | ERG28, PDXK, PAH | M6PR 1089/4885MGAM 1329/4885SI 2726/4885 |
| US-20070042030-A1 | Preparation for the application of agents in mini-droplets | FABP4, NPC1L1, LIPA | M6PR 2907/4885MGAM 165/4885SI 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.